XRCC5 and ductal breast carcinoma in situ: Progression of DCIS lesions was scored using both 2D H&E analysis and a 3D whole-gland imaging technique, which enabled us to identify all human-derived DCIS lesions using human-specific Ku80 immunolabeling.